Non-specific treatment effects and the patient perception of costly drug therapy

Non-specific treatment effects and the patient perception of costly drug therapy European Journal of Clinical Pharmacology (2018) 74:1363 https://doi.org/10.1007/s00228-018-2491-8 LETTER TO THE EDITOR Non-specific treatment effects and the patient perception of costly drug therapy N. W. Boone Received: 18 May 2018 / Accepted: 22 May 2018 / Published online: 31 May 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 In our real-world infliximab transition study among consented come uncertain. After all, the product changes that were made immune-mediated inflammatory disease patients, we corrob- to the originator drug during the patent period did not concern orated a nocebo-effect rate of 13% [1]. any physician or patient [3]. Regarding these results, one can conclude that we did ob- serve a relatively high rate of non-specific treatment effects for costly, Bstate-of-the-art^ drug therapy. This presupposes that References physicians and other healthcare providers have influence on the extent to which patients experience the effect of their med- 1. Boone NW, Liu L, Romberg-camps MJ et al (2018) The nocebo icines. Therefore, the confidence of physicians with effect challenges the nonmedical infliximab switch in practice. Eur biosimilars and the biosimilarity concept is key, which is also J Clin Pharmacol 74(5):655–661 underscored in the study of van Overbeeke et al. [2]. 2. van Overbeeke E, de Beleyr B, de Hoon J, Westhovens R, Huys I (2017) Perception of originator biologics and biosimilars: a survey Given the high degree of uncertainty about the effective- among Belgian rheumatoid arthritis patients and rheumatologists. ness and safety of biosimilars, even in bio-naïve patients, as BioDrugs 31(5):447–459 reported by Pineles and colleagues, it seems that the more 3. Schiestl M, Stangler T (2011) Acceptable changes in quality emphasis is placed on the alleged risk differences between attributes of glycosylated biopharmaceuticals. Nat Biotechnol the originator drug and its biosimilar, the more patients be- 29:310–312 * N. W. Boone nwboone@gmail.com Department of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, PO Box 5500, 6130 MB Sittard-Geleen, The Netherlands http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

Non-specific treatment effects and the patient perception of costly drug therapy

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/non-specific-treatment-effects-and-the-patient-perception-of-costly-oNgAwKUcjm
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
D.O.I.
10.1007/s00228-018-2491-8
Publisher site
See Article on Publisher Site

Abstract

European Journal of Clinical Pharmacology (2018) 74:1363 https://doi.org/10.1007/s00228-018-2491-8 LETTER TO THE EDITOR Non-specific treatment effects and the patient perception of costly drug therapy N. W. Boone Received: 18 May 2018 / Accepted: 22 May 2018 / Published online: 31 May 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 In our real-world infliximab transition study among consented come uncertain. After all, the product changes that were made immune-mediated inflammatory disease patients, we corrob- to the originator drug during the patent period did not concern orated a nocebo-effect rate of 13% [1]. any physician or patient [3]. Regarding these results, one can conclude that we did ob- serve a relatively high rate of non-specific treatment effects for costly, Bstate-of-the-art^ drug therapy. This presupposes that References physicians and other healthcare providers have influence on the extent to which patients experience the effect of their med- 1. Boone NW, Liu L, Romberg-camps MJ et al (2018) The nocebo icines. Therefore, the confidence of physicians with effect challenges the nonmedical infliximab switch in practice. Eur biosimilars and the biosimilarity concept is key, which is also J Clin Pharmacol 74(5):655–661 underscored in the study of van Overbeeke et al. [2]. 2. van Overbeeke E, de Beleyr B, de Hoon J, Westhovens R, Huys I (2017) Perception of originator biologics and biosimilars: a survey Given the high degree of uncertainty about the effective- among Belgian rheumatoid arthritis patients and rheumatologists. ness and safety of biosimilars, even in bio-naïve patients, as BioDrugs 31(5):447–459 reported by Pineles and colleagues, it seems that the more 3. Schiestl M, Stangler T (2011) Acceptable changes in quality emphasis is placed on the alleged risk differences between attributes of glycosylated biopharmaceuticals. Nat Biotechnol the originator drug and its biosimilar, the more patients be- 29:310–312 * N. W. Boone nwboone@gmail.com Department of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, PO Box 5500, 6130 MB Sittard-Geleen, The Netherlands

Journal

European Journal of Clinical PharmacologySpringer Journals

Published: May 31, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off